prof nir london n a calu6 atcc htb 56 mia paca 2 laboratory  (ATCC)

Journal: JCI Insight

Article Title: Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy

doi: 10.1172/jci.insight.174329

Figure Lengend Snippet: ( A ) Dose-response curve of SUM149 cells treated with rigosertib from the high-throughput screen described in Figure 1. Data are the mean ± SD of triplicate samples. ( B – E ) Dose-response curves for rigosertib treatment of HCC1806 ( B ), SUM149 ( C ), A549 ( D ), and Calu6 ( E ) cells growing in RPMI versus HPLM. Data are the mean ± SD of triplicate samples. ( F ) Representative Western blot of phosphorylated histone H3 in HCC1806 cells treated with 150 nM rigosertib in RPMI versus HPLM. ( G and H ) Cell cycle analysis of HCC1806 cells treated with 150 nM commercial-grade rigosertib in RPMI ( G ) and HPLM ( H ). ( I ) Cell death analysis of HCC1806 cells treated with 200 nM commercial-grade rigosertib in RPMI versus HPLM. PI, propidium iodide. Cell death and cell cycle data are the means ± SD of triplicate samples. * indicates P < 0.05 by unpaired 2-tailed t test.

Article Snippet: Cell lines were acquired from the Brugge Lab at Harvard Medical School, Boston, Massachusetts, USA (HCC1806, SUM149); the Kim Rathmell Lab at Vanderbilt University Medical Center, Nashville, Tennessee, USA (A498, 786-O, and Caki2); the Vadim Gaponenko Lab at the University of Illinois at Chicago, Chicago, Illinois, USA (K562); and the ATCC (A549 and Calu6).

Techniques: High Throughput Screening Assay, Western Blot, Cell Cycle Assay